NEW YORK – Biotia said Wednesday that it has entered into a joint development agreement with Mayo Clinic on microbial identification methods for infectious disease diagnostics.
The collaboration involves Biotia's artificial intelligence-based sequence analysis capabilities, which will be used to identify and characterize pathogens isolated from clinical specimens, providing clinicians with detailed strain-level pathogen identities and actionable information. The New York City-based company's platform integrates next-generation sequencing with a curated pathogen database and bioinformatics.
Mayo will contribute expertise in microbial diagnostics, clinical application, data interpretation, and patient care to optimize the platform for real-world clinical use.
Biotia said that resulting diagnostic solutions will be piloted at Mayo Clinic with the potential for broader distribution.
Biotia is a graduate of Mayo's Platform Accelerate program to nurture AI startups.
In November, the New York State Department of Health's Clinical Laboratory Evaluation Program authorized the company's Biotia-ID laboratory-developed test for urinary tract infections.